Tag - SONN

BTIG launched coverage of Sonnet BioTherapeutics (NASDAQ:SONN) with a “buy” rating and price target of $5. The stock closed at 56 cents on Sept. 14. Sonnet is an early-stage biotechnology company working to develop...